The Effectiveness of the Use of Regdanvimab (CT-P59) in Addition to Remdesivir in Patients with Severe COVID-19: A Single Center Retrospective Study
Ganghee Chae, Aram Choi, Soyeoun Lim, Sooneun Park, Seungjun Lee, Youngick Ahn, Jinhyoung Kim, Seungwon Ra, Yangjin Jegal, Jongjoon Ahn, Eunji Park, Jaebum Jun, Woonjung Kwon, Taehoon Lee
Tropical Medicine and Infectious Disease, doi:10.3390/tropicalmed7030051
Introduction: Coronavirus disease 2019 (COVID-19) still has a high mortality rate when it is severe. Regdanvimab (CT-P59), a neutralizing monoclonal antibody that has been proven effective against mild to moderate COVID-19, may be effective against severe COVID-19. This study was conducted to determine the effectiveness of the combined use of remdesivir and regdanvimab in patients with severe COVID-19. Methods: From March to early May 2021, 124 patients with severe COVID-19 were admitted to Ulsan University Hospital (Ulsan, Korea) and received oxygen therapy and remdesivir. Among them, 25 were also administered regdanvimab before remdesivir. We retrospectively compared the clinical outcomes between the remdesivir alone group [n = 99 (79.8%)] and the regdanvimab/remdesivir group [n = 25 (20.2%)]. Results: The oxygenfree days on day 28 (primary outcome) were significantly higher in the regdanvimab/remdesivir group [mean ± SD: 19.36 ± 7.87 vs. 22.72 ± 3.66, p = 0.003]. The oxygen-free days was also independently associated with use of regdanvimab in the multivariate analysis, after adjusting for initial pulse oximetric saturation (SpO 2 )/fraction of inspired oxygen (FiO 2 ) ratio (severity index). Further, in the regdanvimab/remdesivir group, the lowest SpO 2 /FiO 2 ratio during treatment was significantly higher (mean ± SD: 237.05 ± 89.68 vs. 295.63 ± 72.74, p = 0.003), and the Kaplan-Meier estimates of oxygen supplementation days in surviving patients (on day 28) were significantly shorter [mean ± SD: 8.24 ± 7.43 vs. 5.28 ± 3.66, p = 0.024]. Conclusions: In patients with severe COVID-19, clinical outcomes can be improved by administering regdanvimab, in addition to remdesivir.
Author Contributions: Conceptualization, G.C., A.C., W.K. and T.L.; Methodology, A.C., E.P. and T.L.; Formal Analysis, A.C., E.P. and T.L.; Data Curation, A.C. and T.L.; Writing-Original Draft Preparation, T.L.; Writing-Review & Editing, G.C., S.L., S.P., S.L., Y.A., J.K., S.R., Y.J., J.A. and J.J. All authors have read and agreed to the published version of the manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
References
Activ, Ly-Cov555, Group; Lundgren, Grund, Barkauskas et al., A neutralizing monoclonal antibody for hospitalized patients with COVID-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2033130Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of COVID-19-final report, N. Engl. J. Med,
doi:10.1056/NEJMoa2007764Borghesi, Maroldi, COVID-19 outbreak in Italy: Experimental chest X-ray scoring system for quantifying and monitoring disease progression, Radiol. Med,
doi:10.1007/s11547-020-01200-3Choi, Hong, Kim, The association between mortality and the oxygen saturation and fraction of inhaled oxygen in patients requiring oxygen therapy due to COVID-19-associated pneumonia, Tuberc. Respir. Dis,
doi:10.4046/trd.2020.0126Group; Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in hospitalized patients with COVID-19, N. Engl. J. Med,
doi:10.1056/NEJMoa2021436Kim, Jang, Hong, Jung, Park et al., Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection, Clin. Ther,
doi:10.1016/j.clinthera.2021.08.009Kim, Kim, Huh, Choi, Kim et al., Korean Society of Infectious Diseases/National Evidence-based Healthcare Collaborating Agency recommendations for anti-SARS-CoV-2 monoclonal antibody treatment of patients with COVID-19, Infect. Chemother,
doi:10.3947/ic.2021.0304Kim, Ryu, Lee, Kim, Seo et al., A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein, Nat. Commun,
doi:10.1038/s41467-020-20602-5Lee, Lee, Ko, Hyun, Kim et al., Effectiveness of Regdanvimab Treatment in High-Risk COVID-19 Patients to Prevent Progression to Severe Disease, Front. Immunol,
doi:10.3389/fimmu.2021.772320Lee, Lee, Lee, Kim, Lee et al., Regdanvimab in patients with mild-to-moderate SARS-CoV-2 infection: A propensity score-matched retrospective cohort study, Int. Immunopharmacol,
doi:10.1016/j.intimp.2022.108570Lee, Lim, Hong, Park, Kim et al., The primary report of clinical data analysis on the COVID-19 in the Republic of Korea, Public Health Wkly. Rep
Lee, Mcdonald, Butler-Laporte, Harrison, Cheng et al., Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis, Int. J. Infect. Dis,
doi:10.1016/j.ijid.2021.01.065Olivas-Martínez, Cárdenas-Fragoso, Jiménez, Lozano-Cruz, Ortiz-Brizuela et al., In-hospital mortality from severe COVID-19 in a tertiary care center in Mexico City; causes of death, risk factors and the impact of hospital saturation, PLoS ONE,
doi:10.1371/journal.pone.0245772Park, Epidemiology, virology, and clinical features of severe acute respiratory syndrome -coronavirus-2 (SARS-CoV-2; Coronavirus Disease-19), Clin. Exp. Pediatr,
doi:10.3345/cep.2020.00493Regeneron, REGEN-COV™ (Casirivimab and Imdevimab) Phase 3 Recovery Trial Meets Primary Outcome, Improving Survival in Hospitalized COVID-19 Patients Lacking an Immune Response to SARS-COV-2
Rice, Wheeler, Bernard, Hayden, Schoenfeld et al., and Blood Institute ARDS Network. Comparison of the SpO 2 /FIO 2 ratio and the PaO 2 /FIO 2 ratio in patients with acute lung injury or ARDS, Chest,
doi:10.1378/chest.07-0617Ryu, Kang, Noh, Woo, Lee et al., The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2, Biochem. Biophys. Res. Commun,
doi:10.1016/j.bbrc.2021.09.023Sheikh, Mcmenamin, Taylor, Robertson, Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: Demographics, risk of hospital admission, and vaccine effectiveness, Lancet,
doi:10.1016/S0140-6736(21)01358-1Simonis, Serpa Neto, Binnekade, Braber, Bruin et al., Effect of a low vs intermediate tidal volume strategy on ventilator-free days in intensive care unit patients without ARDS: A randomized clinical trial, JAMA,
doi:10.1001/jama.2018.14280Taylor, Adams, Hufford, De La Torre, Winthrop et al., Neutralizing monoclonal antibodies for treatment of COVID-19, Nat. Rev. Immunol,
doi:10.1038/s41577-021-00542-xUlrich, Troxel, Carmody, Eapen, Bäcker et al., Treating COVID-19 with hydroxychloroquine (TEACH): A multicenter, double-blind randomized controlled trial in hospitalized patients, Open Forum Infect. Dis,
doi:10.1093/ofid/ofaa446Waghmare, Xie, Kimball, Yi, Özkök et al., Supplemental oxygen-free days in hematopoietic cell transplant recipients with respiratory syncytial virus, J. Infect. Dis,
doi:10.1093/infdis/jix390Wang, Wang, Identification of risk factors for in-hospital death of COVID-19 pneumonia -lessions from the early outbreak, BMC Infect. Dis,
doi:10.1186/s12879-021-05814-4Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention, JAMA,
doi:10.1001/jama.2020.2648
